Videos

Real-world community oncology data link GLP-1 drugs to 34% lower death risk across cancers, prompting calls for prospective trials.

Samantha Watters, PhD, MPH, discusses the most notable findings about the link connecting social vulnerability, physician access, and unmet need for allogeneic stem cell transplant.

A cross-sectional analysis of 52 first-line trials found post-progression access to effective therapy correlated with OS benefit in targeted therapy but not checkpoint blockade.

Vincent Ma, MD, describes his initial reaction to the July 30, 2026, FDA advisory committee vote on RP1 plus nivolumab in advanced melanoma.

Samantha E. Watters, PhD, MPH, discusses the variables she examined in her research on US states at risk of unmet needs in allogeneic transplant access.

Samantha E. Watters, PhD, MPH, discusses the barriers to access for allogeneic stem cell transplant in the United States.

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC).

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- breast cancer care.

Community oncology improves hereditary cancer care by expanding risk assessment, dense-breast and polyp screening, plus clearer referral pathways.

Dr Joyce Ohm on the future of cancer care: identifying molecular drivers in every tumor to develop truly individualized, targeted therapies.

MCED screening and broader genetic testing push community oncology toward prevention. Learn how practices adapt workflows, training, and follow-up for high-risk patients.

Why genetic tests aren’t enough: learn how counseling, risk models, and ongoing follow-up shape personalized screening and cancer prevention.

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance.

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured follow-up pathways for complex results and high-risk families.

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

Genetic testing reshapes community oncology, expanding hereditary screening to guide personalized surveillance, identify high-risk families, and shift care toward cancer prevention.

Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients.

Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the type of first-line immunotherapy regimen previously received.

Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the importance of optimizing first-line therapy, noting that many patients may not receive multiple subsequent lines of treatment.

Brian C. Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates after stem cell transplant.

Joyce Ohm, PhD, explains how fast genome sequencing now drives targeted cancer therapies, revealing mutations and resistance in real time.

Brian C. Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life.

Menin inhibitors such as ziftomenib and revumenib target NPM1 and KMT2A AML, pushing precision therapy earlier with manageable toxicity.

Obesity rewires DCIS-to-IDC invasion via metabolic stress, inflammatory signaling and SULF2, revealing an immunosuppressive niche

Learn how NPM1 MRD qPCR predicts relapse, shapes transplant decisions, and emerging trials test MRD negativity as a treatment target in AML.

Triplet therapy with ziftomenib, venetoclax, and azacitidine boosts responses in venetoclax‑naive NPM1‑mutated AML; phase 3 trials test frontline benefit.

Joseph Mikhael, MD, MEd, explains the function and potential benefits of the on-body injector now approved for use with isatuximab in multiple myeloma.

Explore how allostatic load, using routine labs and vitals, may strengthen early-onset cancer risk prediction and guide earlier prevention in community oncology.